Organization | Chelsea and Westminster Hospital NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2019

NCT03894124

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Chelsea and Westminster Hospital NHS Foundation Trust | CW plus

Active Ingredients

Drugs in Phase 3 Trials (9)

bictegravir (Biktarvy) (1 trial)

cobicistat (stribild) (1 trial)

darunavir (prezista) (1 trial)

dolutegravir (tivicay) (1 trial)

doravirine (pifeltro) (2 trials)

emtricitabine (emtriva) (1 trial)

tenofovir (viread) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

triple cart regimen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 3)

HIV Infections (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 9